你即將離開本站

並前往https://www.frontiersin.org/articles/288684

From Resistance to Sensitivity: Insights and Implications of ...

Sunitinib, a multityrosine kinase inhibitor, is currently the standard first-line therapy in metastatic renal cell carcinoma (mRCC) and is ...

確定！ 回上一頁

查詢 「Sunitinib」的人也找了：

  1. sunitinib機轉
    2.
  2. sunitinib健保
    3.
  3. sunitinib仿單
    4.
  4. sunitinib副作用
    5.
  5. sunitinib標靶
    6.
  6. Sunitinib
    7.
  7. 舒癌特療程
    8.
  8. Sorafenib
    9.